Medicine and HealthNot specified in provided text
Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer
H. Hockings, E. Lakatos, et al.
Discover how Adaptive Therapy (AT) is revolutionizing the treatment of chemotherapy-resistant ovarian cancer, potentially leading to better patient outcomes. Conducted by renowned researchers including Helen Hockings and Eszter Lakatos, this study reveals how exploiting the fitness costs of drug-resistant cells can extend survival in ovarian cancer patients. Intriguing findings from patient samples further support the potential of AT, paving the way for a multicenter phase 2 trial.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Veterinary Science
Long-term efficacy of BCG vaccination in goat herds with a high prevalence of tuberculosis
C. Arrieta-villegas, A. Allepuz, et al.
Medicine and Health
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
J. Cortés, S. A. Hurvitz, et al.
Medicine and Health
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
D. H. Ryan, I. Lingvay, et al.
Medicine and Health
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
H. M. Colhoun, I. Lingvay, et al.
